

REMARKS

Applicants respectfully request entry of the amendments hereinabove, and an early examination and allowance of the claims.

Applicants also claim priority from the applications detailed in the amendment to the specification and request acknowledgment of such claim.

Applicants have herein cancelled all the original claims except claim 1 which has been retained so that one original independent claim is retained for filing purposes.

Applicants have added a new set of claims related to the combination of a cGMP PDE5 inhibitor and gabapentin or pregabalin. New claims 17 through 26 are directed to a pharmaceutical combination or composition and new claims 27 through 34 are directed to a method of treatment.

Applicants submit that the amendment (e.g., new claims) is fully supported. Applicant further submits that the literal basis for such amendment is not required to be found in the specification (the claim phrase need not be "*in haec verba*" in the specification *In Re Wright* 9 U.S.P.Q.2d 1649, 1651 (Fed. Cir. 1989); *Crowne Operations, Int'l, Inc. v. Solutia, Inc.* 289 F.3d 1367, 1376 (Fed. Cir. 2002)).

Applicants submit that the claims are supported as follows:
Claims 17 and 18 are supported by page 1, lines 3-6; page 11, lines 34-35; page 12, line 10; page 10, lines 10-16 and page 9, lines 1-4 of the specification.
Claims 19-21 and 24-26 are supported by claims 12-16 as originally filed.
Claims 22 and 23 are supported by page 12, line 10 of the specification.
Claim 27 is supported by page 1, lines 3-6; page 11, lines 34-35; page 12, line 10; page 10, lines 10-16 and page 9, lines 1-4 of the specification.
Claims 28-32 are supported by claims 10-16 as originally filed.
Claims 33 and 34 are supported by page 12, line 10 of the specification.

Applicants note that the support for the combination agents pregabalin and gabapentin is found on page 12, line 10 "pregabalene; gabapentene". Applicants have corrected the clerical spelling error in the generic names of the compounds in the claims. Applicants note that pregabalin was published as a USAN name in 1997 and gabapentin was published as a USAN name in 1989.

Applicants note that support for the selectivity ratio of 100 may be found in the specification on page 8, lines 25-26.

Applicants note that they will be filing an Information Disclosure Statement soon and will likely be amending the Inventorship in this instant application.

Please charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 16-1445. Two copies of this sheet are enclosed.

Respectfully submitted,



A. Dean Olson
Reg. No. 31,185
Attorney for Applicant

Date: December 10, 2003

Pfizer Inc.
Patent Department MS 8260-1611
Eastern Point Road
Groton, CT 06340
Tel.: (860) 441-4904